Choose Your Country or Region

Tafamidis

Name: Tafamidis
Brand: Selleck Chemicals
SKU: S6465
Rating: 5 (1 reviews)

Catalog No.S6465 Purity: 99.98%

Tafamidis is a kinetic stabilizer of transthyretin (TTR) that prevents amyloidogenesis by wild-type and mutant TTRs.

Tafamidis Chemical Structure

CAS: 594839-88-0

Purity & Quality Control

Batch: S646501 DMSO] 31 mg/mL] false] Water] Insoluble] false] Ethanol] Insoluble] false Purity: 99.98%

99.98

Tafamidis Related Products

Related Targets	5-HT1 5-HT2 5-HT3 5-HT4 5-HT6 5-HT7 5-HT5	Click to Expand
Related Products	Olanzapine Aripiprazole Puerarin Clozapine WAY-100635 Maleate Serotonin (5-HT) HCl Citalopram HBr Prucalopride BRL-15572 Dihydrochloride SB269970 HCl Trazodone Prucalopride Succinate Ketanserin RS-127445 Agomelatine (S20098) Risperidone Pimavanserin tartrate Azacyclonol Tegaserod Maleate Nuciferine Flopropione Vilazodone HCl SB742457 Almotriptan Malate BRL 15572 BRL-54443 Perospirone hydrochloride Alverine Citrate Cyproheptadine hydrochloride sesquihydrate Buspirone HCl Cisapride hydrate Alosetron Hydrochloride Loxapine Succinate Flibanserin Ondansetron Ramosetron Hydrochloride Trazodone HCl SB 271046 hydrochloride Zolmitriptan PRX-08066 Maleic acid Thioridazine hydrochloride Blonanserin Vilazodone	Click to Expand
Related Compound Libraries	FDA-approved Drug Library Natural Product Library Neuronal Signaling Compound Library CNS-Penetrant Compound Library Anti-alzheimer Disease Compound Library	Click to Expand

Signaling Pathway

5-HT Receptor Signaling Pathway

Choose Selective 5-HT Receptor Inhibitors

Biological Activity

Description	Tafamidis is a kinetic stabilizer of transthyretin (TTR) that prevents amyloidogenesis by wild-type and mutant TTRs.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2024-01-11)
NCT05938218	Not yet recruiting	Amyloidosis Cardiac\|Virtual Reality	Heinrich-Heine University Duesseldorf	December 1 2023	Not Applicable
NCT06086353	Not yet recruiting	Transthyretin Amyloid Cardiomyopathy	Pfizer	October 20 2023	--
NCT05489523	Recruiting	Transthyretin Cardiac Amyloidosis	University of Texas Southwestern Medical Center	May 1 2023	Phase 4
NCT05560555	Completed	Hereditary Transthyretin Amyloidosis (ATTRv)\|Polyneuropathy	Pfizer	October 24 2022	--
NCT05374564	Recruiting	Cardiomyopathies Primary	Yale University\|Pfizer	August 16 2022	Phase 1
NCT04814186	Completed	Transthyretin Amyloid Cardiomyopathy	Pfizer	July 22 2021	Phase 4

Chemical Information & Solubility

Molecular Weight	308.12	Formula	C₁₄H₇Cl₂NO₃
CAS No.	594839-88-0	SDF	--
Smiles	C1=CC2=C(C=C1C(=O)O)OC(=N2)C3=CC(=CC(=C3)Cl)Cl
Storage (From the date of receipt)	3 years -20°C powder	Storage of Stock Solutions Aliquot the stock solutions to avoid repeated freeze-thaw cycles	1 year-80°Cin solvent
Storage (From the date of receipt)	3 years -20°C powder		1 month-20°Cin solvent

In vitro
Batch:

DMSO : 31 mg/mL ( (100.61 mM)； Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Water : Insoluble

Ethanol : Insoluble

Molecular Weight Calculator

In vivo
Batch:

Add solvents to the product individually and in order.

In vivo Formulation Calculator

Preparing Stock Solutions

Molarity Calculator

Dilution Calculator Molecular Weight Calculator

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):